Myrlosar Comp (Losartan Potassium, Hydrochlorothiazide)

Losartan potassium is an angiotensin II receptor blocker (ARB). It selectively binds to AT1 receptors on blood‑vessel smooth muscle and adrenal glands, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxed vessels, reduced sodium retention and lower blood pressure.

The specific dose of Myrlosar Comp is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and other medical considerations. Dosage may be adjusted over time, and patients should follow the exact instructions provided on the prescription label.

Safety of Myrlosar Comp in pregnancy has not been established, and it is generally avoided unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in milk and may affect the infant.

To request Myrlosar Comp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, Myrlosar Comp offers combined blockade of the renin‑angiotensin system and diuretic‑induced fluid loss, often achieving greater blood‑pressure reduction at lower individual doses. It may be preferred when monotherapy does not provide sufficient control, but clinicians consider patient tolerance, renal function and electrolyte balance.

Myrlosar Comp tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Myrlosar Comp is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe allergic reactions (anaphylaxis), acute kidney injury, hyperkalemia, and marked hypotension. Patients should be educated to seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of urine output, severe dizziness or fainting.

Myrlosar Comp is contraindicated in patients with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, anuria, or those taking other potassium‑sparing agents without close monitoring.